DDInter1266 DDInter1024
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Lapatinib
Naproxen {u} (Compound) upregulates {v} (Gene) VAV3
VAV3 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Nail disorder
Nail disorder {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Naproxen {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Naproxen {u} (Compound) upregulates {v} (Gene) VAV3
VAV3 {u} (Gene) interacts with {v} (Gene) EGFR
EGFR {u} (Gene) is bound by {v} (Compound) Lapatinib
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
FAM63A {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is bound by {v} (Compound) Lapatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Nail disorder
Nail disorder {u} (Side Effect) is caused by {v} (Compound) Imatinib
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Naproxen {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lapatinib
Naproxen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Hypersensitivity {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Lapatinib (Compound)
Naproxen (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) is upregulated by Lapatinib (Compound)
Naproxen (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Lapatinib (Compound)
Naproxen (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Naproxen (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) interacts with EGFR (Gene) and EGFR (Gene) is bound by Lapatinib (Compound)
Naproxen (Compound) upregulates FAM63A (Gene) and FAM63A (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is bound by Lapatinib (Compound)
Naproxen (Compound) causes Nail disorder (Side Effect) and Nail disorder (Side Effect) is caused by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Naproxen (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Naproxen (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Naproxen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Lapatinib (Compound)